1. Malaysia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Duopharma Biotech Bhd.

Duopharma Biotech Bhd.

MMYX:DPHARMA
1.09
MYR
-0.01
(-0.91%)
11.20P/E
Nov 11Next Earn
Duopharma Biotech Bhd.
MYX:DPHARMA
(Bursa Malaysia)

Recent

price

1.09

P/E

ratio

11.20

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
MYR
0.23
0.24
0.23
0.28
0.3
0.43
0.36
0.54
0.57
0.65
0.61
0.69
0.73
0.74
0.85
0.97
0.97
Revenue per Share
0.05
0.05
0.04
0.06
0.06
0.06
0.03
0.05
0.05
0.06
0.06
0.07
0.07
0.05
0.07
0.09
0.11
Basic EPS, GAAP
0.02
0.02
0.05
0.05
0.04
-0.15
- -
-0.02
-0.02
0.01
0.01
-0.08
- -
0.01
0.05
0.08
0.06
Free Cash Flow per Basic Share
0.04
0.03
0.03
0.03
0.04
0.05
0.03
0.02
0.02
0.01
0.01
0.05
0.01
0.01
0.03
0.04
0.05
Dividend per Share
0.27
0.28
0.29
0.31
0.33
0.52
0.52
0.55
0.55
0.58
0.68
0.66
0.69
0.71
0.74
0.79
0.82
Book Value per Share
0.27
0.28
0.29
0.31
0.33
0.51
0.51
0.53
0.52
0.55
0.65
0.62
0.64
0.67
0.69
0.75
0.78
Tangible Book Value per Share
583
583
583
583
583
627
868
868
875
894
928
928
948
959
962
962
962
Basic Weighted Avg Shares
131
138
135
162
177
270
313
468
499
576
570
639
697
705
814
932
929
Sales/Revenue/Turnover
26.57
25.04
26.31
24.74
26.43
18.6
10.22
11.5
13.53
13.47
14.22
13.9
13.27
11.75
12.37
14.36
16.35
Operating Margin (%)
5
6
7
8
8
22
23
24
25
27
29
32
36
43
45
46
45
Depreciation Expense
29
27
26
32
35
36
27
42
48
55
59
66
70
53
63
87
102
Net Income, GAAP
19.03
23.1
26.3
19.66
24.14
23.91
14.78
17.98
20.15
21.94
23.04
20.85
17.37
16.79
21.72
23.88
23.9
Effective Tax Rate (%)
21.81
19.33
19.23
19.87
19.93
13.49
8.57
9.07
9.55
9.59
10.28
10.28
10.06
7.47
7.7
9.39
11
Profit Margin (%)
72
70
71
76
84
280
263
235
145
178
309
264
277
510
548
505
543
Working Capital
10
2
- -
- -
- -
104
92
91
122
141
254
300
297
482
467
345
337
LT Debt
158
164
171
183
194
450
455
480
481
530
644
624
655
687
709
758
786
Total Equity
16.83
15.05
14.94
17.96
18.7
9.95
4.78
7.51
8.08
7.97
7.15
7.1
7.2
5.93
6.4
8.21
9.26
Return on Invested Capital (%)
17.08
15.23
14.99
18.16
18.75
10.22
5.5
7.92
8.06
8.09
7.3
7.17
7.34
5.8
6.78
8.59
9.67
Return on Capital (%)
19.07
16.57
15.53
18.28
18.75
11.31
5.93
9.09
9.92
10.94
9.99
10.36
10.96
7.84
8.97
11.93
13.43
Return on Common Equity (%)

Capital Structure

MYR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
147
141
135
LT Borrowings
345
341
337
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
962
962
962
Market Capitalization
1,202
1,222
1,145

Working Capital

MYR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
819
825
844
Cash, Cash Equivalents & STI
291
271
256
Accounts Receivable, Net
224
253
277
Inventories
293
297
305
Total Current Liabilities
314
315
301
Payables & Accruals
- -
- -
- -
ST Debt
147
141
135
Deferred Revenue
- -
- -
- -

Growth Rates

MYR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.54%
3.37%
6.84%
Free Cash Flow
-132.79%
-458.01%
49.33%
Net Income, GAAP
11.88%
10.5%
39.62%
Sales/Revenue/Turnover
13.88%
10.45%
14.5%
Total Cash Common Dividend
56.75%
135.44%
25%

Quarterly Revenue

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
193
218
209
194
814
2025
263
222
222
225
932
2026
248
234
- -
- -
- -

Quarterly Earnings Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.02
0.02
0.07
2025
0.03
0.02
0.02
0.02
0.09
2026
0.03
0.03
- -
- -
- -

Quarterly Dividends Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
0.01
- -
0.03
2025
0.02
- -
0.02
- -
0.04
2026
0.03
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Duopharma Biotech Berhad, an investment holding company listed on Bursa Malaysia (7148.KL), researches, develops, manufactures, distributes and imports pharmaceutical products and medicines primarily in Malaysia and select export markets. The company offers a broad portfolio of generic and halal-certified pharmaceuticals in forms including tablets, capsules, syrups, oral antibiotics, creams, hemodialysis solutions, sterile irrigation solutions, sterile powders, small volume injectables, dental cartridges and eye drops; over-the-counter consumer healthcare products under brands such as Champs, Flavettes, Proviton, Naturalle, Uphamol, Eye Glo, Donna and Alucid encompassing analgesics, antihistamines and related categories; prescription products under the Omesec brand; and specialty offerings including biopharmaceuticals, biosimilars and insulin products developed in partnership with entities like Biocon. Founded in 1979 with roots tracing to 1978 and headquartered in Klang, Selangor, Malaysia, Duopharma Biotech operates manufacturing facilities in Klang, Bangi and Glenmarie, with subsidiaries in the Philippines and Singapore, a representative office in Indonesia and exports to Vietnam, Ethiopia, Sudan, Southeast Asia, Papua New Guinea, Pakistan, Bangladesh, Sri Lanka, Yemen, Singapore and Hong Kong; it functions as a subsidiary of Permodalan Nasional Berhad following a name change from CCM Duopharma Biotech Berhad in February 2019. Recent developments include securing MYR578 million supply contracts in April 2024 under the government's approved products purchase list, including insulin supplies via Pharmaniaga; clinching additional supply deals from Pharmaniaga; achieving first-in-Malaysia halal certification for a biosimilar product under MS2424:2019; shifting production to the new K3 facility for optimization while planning expansions at K2 and K5 for biologicals capability; and opening an office in Indonesia to enhance ASEAN presence, alongside expected earnings growth from a stronger ringgit, lower API costs and full-year contributions from 2024 contracts.